Moma Therapeutics
Apr 16, 2020
Vir’s drug shows results; Abbott launches coronavirus antibody lab test; Reprogrammed skin cells repair vision in mouse models; Moma Therapeutics focuses for molecular machines
Vir's Hepatitis B drug shows positive results in phase 2 The hepatitis B drug of Vir Biotechnology has shown promising results. Its gene-silencing drug trim levels of the hepatitis B surface antigen in a small phase 2 study in patients who are already taking antiretroviral drugs. The drug, VIR-2218,...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
